Literature DB >> 10477685

Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors.

S Fichelson1, J M Freyssinier, F Picard, M Fontenay-Roupie, M Guesnu, M Cherai, S Gisselbrecht, F Porteu.   

Abstract

In several erythroleukemia cell lines, activation of mitogen-activated protein kinases (MAPK) by phorbol esters or megakaryocyte growth and development factor (MGDF) is required for induction of megakaryocytic phenotype and growth arrest. To support this model, we have examined the effect of a specific inhibitor of this pathway (PD98059) on human CD34(+) hematopoietic progenitors isolated from cord blood (CB), induced to differentiate along the megakaryocytic lineage in liquid cultures supplemented with rhuMGDF. RhuMGDF induced a sustained activation of MAPK in megakaryocytes and this activation was completely inhibited in the presence of low concentrations of PD98059 (6 to 10 micromol/L). At this concentration, PD98059 induced an increase in cell proliferation, resulting in accumulation of viable cells and a prolongation of the life time of the cultures. This increase correlated with an increase in DNA synthesis rather than with a reduction in apoptosis. This effect was combined with developmental changes indicative of delayed megakaryocytic differentiation: (1) PD98059-treated cells tended to retain markers of immature progenitors as shown by the increased proportion of both CD34(+) and CD41(+)CD34(+) cells. (2) PD98059-treated cultures were greatly enriched in immature blasts cells. (3) PD98059 increased megakaryocytic progenitors able to form colonies in semisolid assays. Thus, the MAPK pathway, although not required for megakaryocyte formation, seems to be involved in the transition from proliferation to maturation in megakaryocytes. Inhibition of MAPK activation also led to an increase in the number and size of erythroid colonies without affecting granulocyte/macrophage progenitor numbers suggesting that, in addition to the megakaryocytic lineage, the MAPK pathway could play a role in erythroid lineage differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Megakaryopoiesis.

Authors:  Amy E Geddis
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

2.  Protein-arginine methyltransferase 1 suppresses megakaryocytic differentiation via modulation of the p38 MAPK pathway in K562 cells.

Authors:  Yuan-I Chang; Wei-Kai Hua; Chao-Ling Yao; Shiaw-Min Hwang; Yi-Chi Hung; Chih-Jen Kuan; Jiun-Shyang Leou; Wey-Jinq Lin
Journal:  J Biol Chem       Date:  2010-05-04       Impact factor: 5.157

3.  Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.

Authors:  Christian A Di Buduo; Vittorio Abbonante; Caroline Marty; Francesco Moccia; Elisa Rumi; Daniela Pietra; Paolo M Soprano; Dmitry Lim; Daniele Cattaneo; Alessandra Iurlo; Umberto Gianelli; Giovanni Barosi; Vittorio Rosti; Isabelle Plo; Mario Cazzola; Alessandra Balduini
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

Review 4.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

5.  Exposure of pregnant sows to deoxynivalenol during 35-70 days of gestation does not affect pathomorphological and immunohistochemical properties of fetal organs.

Authors:  Wolf Wippermann; Anne Heckmann; Kathrin Jäger; Sven Dänicke; Heinz-Adolf Schoon
Journal:  Mycotoxin Res       Date:  2017-12-29       Impact factor: 3.833

Review 6.  Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions.

Authors:  Philip J S Stork; Tara J Dillon
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

7.  Thrombopoietin upregulates nucleolin mRNA and protein in thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO.

Authors:  Takatoshi Ito; Mitsuhiro Fujihara; Atsushi Oda; Shinobu Wakamoto; Miki Yamaguchi; Norio Komatsu; Hiroshi Miyazaki; Hiroshi Azuma; Hisami Ikeda; Kenji Ikebuchi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

Review 8.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Authors:  Giampaolo Tortora; Roberto Bianco; Gennaro Daniele; Fortunato Ciardiello; James A McCubrey; Maria Rosaria Ricciardi; Ludovica Ciuffreda; Francesco Cognetti; Agostino Tafuri; Michele Milella
Journal:  Drug Resist Updat       Date:  2007-05-07       Impact factor: 18.500

Review 9.  Molecular control of megakaryopoiesis and thrombopoiesis.

Authors:  Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

10.  Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation.

Authors:  Alexandra Mazharian; Steve P Watson; Sonia Séverin
Journal:  Exp Hematol       Date:  2009-07-18       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.